Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Deadly public policy: what the future could hold for the HIV epidemic among injection drug users in Vancouver.

O'Shaughnessy MV, Hogg RS, Strathdee SA, Montaner JS.

Curr HIV/AIDS Rep. 2012 Dec;9(4):394-400. doi: 10.1007/s11904-012-0130-z. Review.

PMID:
22773331
2.

Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort.

Braitstein P, Montessori V, Chan K, Montaner JS, Schechter MT, O'Shaughnessy MV, Hogg RS.

AIDS Care. 2005 May;17(4):505-15.

PMID:
16036236
3.

Incarceration, addiction and harm reduction: inmates experience injecting drugs in prison.

Small W, Kain S, Laliberte N, Schechter MT, O'Shaughnessy MV, Spittal PM.

Subst Use Misuse. 2005;40(6):831-43.

PMID:
15974143
4.

The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS.

Anis AH, Guh D, Hogg RS, Wang XH, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS.

Pharmacoeconomics. 2000 Oct;18(4):393-404.

PMID:
15344307
5.

Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

Antivir Ther. 2004 Apr;9(2):229-35.

PMID:
15134185
6.

The impact of adherence on CD4 cell count responses among HIV-infected patients.

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):261-8.

PMID:
15076240
7.

Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA.

Montaner JS, Côté HC, Harris M, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV.

Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S73-9.

PMID:
14986278
8.

Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.

O'Connell JM, Braitstein P, Hogg RS, Yip B, Craib KJ, O'Shaughnessy MV, Montaner JS, Burdge DR.

Antivir Ther. 2003 Dec;8(6):569-76.

PMID:
14760890
9.

Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.

Palepu A, Tyndall MW, Li K, Yip B, O'Shaughnessy MV, Schechter MT, Montaner JS, Hogg RS.

J Urban Health. 2003 Dec;80(4):667-75.

10.

HIV-positive injection drug users who leave the hospital against medical advice: the mitigating role of methadone and social support.

Chan AC, Palepu A, Guh DP, Sun H, Schechter MT, O'Shaughnessy MV, Anis AH.

J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):56-9.

PMID:
14707793
11.
12.

Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill.

Delgado J, Heath KV, Yip B, Marion S, Alfonso V, Montaner JS, O'Shaughnessy MV, Hogg RS.

Antivir Ther. 2003 Oct;8(5):471-8.

PMID:
14640395
13.

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.

Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):395-402.

PMID:
14640386
14.

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.

PMID:
14640384
15.

Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.

Wood E, Hogg RS, Yip B, Quercia R, Harrigan PR, O'Shaughnessy MV, Montaner JS.

J Infect Dis. 2003 Nov 15;188(10):1421-5. Epub 2003 Nov 5.

PMID:
14624366
16.
17.

CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.

Wood E, Hogg RS, Yip B, O'Shaughnessy MV, Montaner JS.

J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):347-8. No abstract available.

PMID:
14600584
18.

Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world.

Wood E, Montaner JS, Bangsberg DR, Tyndall MW, Strathdee SA, O'Shaughnessy MV, Hogg RS.

AIDS. 2003 Nov 21;17(17):2419-27. Review. No abstract available.

PMID:
14600512
19.

Requiring help injecting as a risk factor for HIV infection in the Vancouver epidemic: implications for HIV prevention.

Wood E, Spittal PM, Kerr T, Small W, Tyndall MW, O'Shaughnessy MV, Schechter MT.

Can J Public Health. 2003 Sep-Oct;94(5):355-9.

PMID:
14577743
20.

Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy.

Montaner JS, Côté HC, Harris M, Hogg RS, Yip B, Chan JW, Harrigan PR, O'Shaughnessy MV.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S85-90. Review.

PMID:
14562863
21.

Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy.

Wood E, Montaner JS, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

J Infect Dis. 2003 Oct 15;188(8):1164-70. Epub 2003 Oct 1.

PMID:
14551887
22.

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

CMAJ. 2003 Sep 30;169(7):656-61.

23.

Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000.

Braitstein P, Yip B, Heath KV, Levy AR, Montaner JS, Humphries K, Kiely FM, O'Shaughnessy MV, Hogg RS.

AIDS. 2003 Sep 26;17(14):2071-5.

PMID:
14502010
24.

An external evaluation of a peer-run "unsanctioned" syringe exchange program.

Wood E, Kerr T, Spittal PM, Small W, Tyndall MW, O'Shaughnessy MV, Schechter MT.

J Urban Health. 2003 Sep;80(3):455-64.

25.

Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.

Alexander CS, Asselin JJ, Ting LS, Montaner JS, Hogg RS, Yip B, O'Shaughnessy MV, Harrigan PR.

J Infect Dis. 2003 Aug 15;188(4):541-8. Epub 2003 Jul 29.

PMID:
12898441
26.

Surviving the sex trade: a comparison of HIV risk behaviours among street-involved women in two Canadian cities who inject drugs.

Spittal PM, Bruneau J, Craib KJ, Miller C, Lamothe F, Weber AE, Li K, Tyndall MW, O'Shaughnessy MV, Schechter MT.

AIDS Care. 2003 Apr;15(2):187-95.

PMID:
12856340
27.

Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance.

Galli RA, Sattha B, Wynhoven B, O'Shaughnessy MV, Harrigan PR.

J Clin Microbiol. 2003 Jul;41(7):2900-7.

28.

Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy.

Lee N, Hogg RS, Yip B, Harrigan PR, Harris M, O'Shaughnessy MV, Montaner JS.

J Infect Dis. 2003 Jul 1;188(1):137-41. Epub 2003 Jun 23.

PMID:
12825182
29.

Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

Côté HC, Yip B, Asselin JJ, Chan JW, Hogg RS, Harrigan PR, O'Shaughnessy MV, Montaner JS.

J Infect Dis. 2003 Jun 15;187(12):1972-6. Epub 2003 May 29.

PMID:
12792876
30.

The impact of needle-exchange programs on the spread of HIV among injection drug users: a simulation study.

Raboud JM, Boily MC, Rajeswaran J, O'Shaughnessy MV, Schechter MT.

J Urban Health. 2003 Jun;80(2):302-20.

31.

Sexual violence among a cohort of injection drug users.

Braitstein P, Li K, Tyndall M, Spittal P, O'Shaughnessy MV, Schilder A, Johnston C, Hogg RS, Schechter MT.

Soc Sci Med. 2003 Aug;57(3):561-9.

PMID:
12791497
32.

Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.

Brumme ZL, Chan KJ, Dong WW, Wynhoven B, Mo T, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR.

Antivir Ther. 2003 Apr;8(2):91-6.

PMID:
12741620
33.

Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based setting.

Jahnke N, Seminari E, Hogg RS, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 1999;4(3):151-6.

PMID:
12731754
34.

High pregnancy rates and reproductive health indicators among female injection-drug users in Vancouver, Canada.

Weber AE, Tyndall MW, Spittal PM, Li K, Coulter S, O'Shaughnessy MV, Schechter MT.

Eur J Contracept Reprod Health Care. 2003 Mar;8(1):52-8.

PMID:
12725675
35.

Predictors of early hospital readmission in HIV-infected patients with pneumonia.

Palepu A, Sun H, Kuyper L, Schechter MT, O'Shaughnessy MV, Anis AH.

J Gen Intern Med. 2003 Apr;18(4):242-7.

36.

Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.

Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS.

J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):522-6.

PMID:
12679704
37.

Health and socioeconomic status differences among antibody hepatitis C positive and negative transfusion recipients, 1986-1990.

Hogg RS, Craib KJ, Pi D, Lee SS, Minuk GY, Shapiro CM, Schechter MT, O'Shaughnessy MV.

Can J Public Health. 2003 Mar-Apr;94(2):130-4.

PMID:
12675170
38.

Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic.

Tyndall MW, Currie S, Spittal P, Li K, Wood E, O'Shaughnessy MV, Schechter MT.

AIDS. 2003 Apr 11;17(6):887-93.

PMID:
12660536
39.

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

AIDS. 2003 Mar 28;17(5):711-20.

PMID:
12646794
40.

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response.

Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR.

AIDS. 2003 Jan 24;17(2):201-8.

PMID:
12545080
41.

Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure.

Wood E, Tyndall MW, Spittal PM, Li K, Anis AH, Hogg RS, Montaner JS, O'Shaughnessy MV, Schechter MT.

CMAJ. 2003 Jan 21;168(2):165-9.

42.

Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection.

Heath KV, Montaner JS, Bondy G, Singer J, O'Shaughnessy MV, Hogg RS.

Curr Drug Targets. 2003 Jan;4(1):13-22. Review.

PMID:
12528986
43.

Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver.

Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, Heath K, Tyndall MW, O'Shaughnessy MV, Schechter MT.

CMAJ. 2003 Jan 7;168(1):19-24.

44.

The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users.

Wood E, Kerr T, Spittal PM, Li K, Small W, Tyndall MW, Hogg RS, O'Shaughnessy MV, Schechter MT.

J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):2-8.

PMID:
12514408
45.

Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.

Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS.

Int J Epidemiol. 2002 Oct;31(5):1016-20.

PMID:
12435777
46.

Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy.

Heath KV, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):211-7.

PMID:
12394800
47.

Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996.

Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangsberg D, O'Shaughnessy MV, Hogg RS.

AIDS. 2002 Oct 18;16(15):2065-72.

PMID:
12370506
48.

Leaving hospital against medical advice among HIV-positive patients.

Anis AH, Sun H, Guh DP, Palepu A, Schechter MT, O'Shaughnessy MV.

CMAJ. 2002 Sep 17;167(6):633-7.

49.

Satellite needle distribution among injection drug users: policy and practice in two canadian cities.

Tyndall MW, Bruneau J, Brogly S, Spittal P, O'Shaughnessy MV, Schechter MT.

J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):98-105.

PMID:
12352156
50.

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.

Brumme ZL, Chan KJ, Dong WW, Mo T, Wynhoven B, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR.

AIDS. 2002 Sep 27;16(14):1929-33.

PMID:
12351953

Supplemental Content

Loading ...
Support Center